NBY Quote, Financials, Valuation and Earnings

Matinas BioPharma Holdings has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Matinas BioPharma Holdings's return on equity of --.

NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 31.62%. On the other hand Matinas BioPharma Holdings has an analysts' consensus of -- which suggests that it could grow by 2900%. Given that Matinas BioPharma Holdings has higher upside potential than NovaBay Pharmaceuticals, analysts believe Matinas BioPharma Holdings is more attractive than NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals has a beta of 0.443, which suggesting that the stock is 55.681% less volatile than S&P 500. In comparison Matinas BioPharma Holdings has a beta of 1.310, suggesting its more volatile than the S&P 500 by 30.998%.

NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Matinas BioPharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Matinas BioPharma Holdings pays out -- of its earnings as a dividend.

NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Matinas BioPharma Holdings quarterly revenues of --. NovaBay Pharmaceuticals's net income of $7.7M is higher than Matinas BioPharma Holdings's net income of -$1.7M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Matinas BioPharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.16x versus 1.18x for Matinas BioPharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Nanoviricides has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Nanoviricides's return on equity of --.

NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 31.62%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 306.25%. Given that Nanoviricides has higher upside potential than NovaBay Pharmaceuticals, analysts believe Nanoviricides is more attractive than NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals has a beta of 0.443, which suggesting that the stock is 55.681% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Nanoviricides quarterly revenues of --. NovaBay Pharmaceuticals's net income of $7.7M is higher than Nanoviricides's net income of -$2.2M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.16x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Oragenics's return on equity of --.

NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 31.62%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Oragenics is more attractive than NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals has a beta of 0.443, which suggesting that the stock is 55.681% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Oragenics quarterly revenues of --. NovaBay Pharmaceuticals's net income of $7.7M is higher than Oragenics's net income of -$2.2M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.16x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -49.65% compared to NovaBay Pharmaceuticals's net margin of --. NovaBay Pharmaceuticals's return on equity of -461.38% beat Theriva Biologics's return on equity of --.

NovaBay Pharmaceuticals has a consensus price target of $0.85, signalling upside risk potential of 31.62%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Theriva Biologics is more attractive than NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals has a beta of 0.443, which suggesting that the stock is 55.681% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

NovaBay Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovaBay Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

NovaBay Pharmaceuticals quarterly revenues are $2.4M, which are larger than Theriva Biologics quarterly revenues of --. NovaBay Pharmaceuticals's net income of $7.7M is higher than Theriva Biologics's net income of -$4.3M. Notably, NovaBay Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovaBay Pharmaceuticals is 0.16x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.